Y. Sun

发表

A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC).

H. Wildiers, J. Jassem, L. Dirix, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study.

B. Rini, C. Szczylik, B. Escudier, 2011, Journal of Clinical Oncology.

Improvement of productivity of yeast cell with a novel airlift loop reactor.

G. T. Tsao, D. Liu, Y. Sun, 1996, Applied biochemistry and biotechnology.

Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.

R. Pérez-Carrión, Y. Sun, H. Mouridsen, 2004, The oncologist.

The role of ifosfamide and cyclophosphamide in the multi-modality treatment after surgery for cure for small-cell bronchial carcinomas (SCLC)

M. Liao, F. Bruno, Y. Sun, 1989, Medical oncology and tumor pharmacotherapy.

Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study.

K. Blackwell, K. Zaman, V. Diéras, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Observation of the first line treatment for patients with Stage IIIB-IV non-squamous non-small cell lung cancer by bevacizumab combined with paclitaxel and carboplatin

Y. Sun, 2013 .

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1331PDetection of EGFR T790M in Asia-Pacific patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Circulating tumour (ct) DNA analysis across 3 platforms

S. Patel, Y. Wu, C. Zhou, 2017 .

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC).

R. Herbst, N. Saijo, B. Johnson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and pharmacokinetics (PK) of AMG 706 with panitumumab plus FOLFIRI or FOLFOX for the treatment of patients (pts) with metastatic colorectal cancer (mCRC)

H. Hurwitz, D. Goldstein, H. Burris, 2007 .

Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC).

G. Gladish, R. Salgia, A. Sandler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas

M. Rettig, Y. Sun, M. Fisher, 2004, Leukemia.

Two Years of Anti-Androgen Treatment Increases Other-Cause Mortality in Men Receiving Early Salvage Radiotherapy: A Secondary Analysis of the NRG Oncology/RTOG 9601 Randomized Phase III Trial

A. Zietman, H. Sandler, R. Dess, 2019, International Journal of Radiation Oncology*Biology*Physics.

Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer: a retrospective analysis in clinical N0 patients.

L. Kong, Y. Sun, X. Zhang, 2018, Current oncology.

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

C. Boni, H. Mouridsen, F. Jänicke, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative CT texture analysis of gastric cancer: correlations with postoperative TNM staging.

C. Ji, Y. Ge, W. Guan, 2018, Clinical radiology.

865P A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent, or metastatic cervical cancer (CC)

Jianji Pan, Yi-Ling Lin, Li Li, 2020 .

Pembrolizumab vs chemotherapy in patients with advanced/metastatic adenocarcinoma (AC) or squamous cell carcinoma (SCC) of the esophagus as second-line therapy: Analysis of the Chinese subgroup in KEYNOTE-181

L. Shen, Y. Cheng, S. Qin, 2019, Annals of Oncology.

A multicenter phase II study of the efficacy and safety of docetaxel plus cisplatin in Asian chemonaïve patients with metastatic or locally advanced non-small cell lung cancer.

E. Tan, Z. Guan, M. Liao, 2003, Respiratory medicine.

Texture analysis of CT images in predicting malignancy risk of gastrointestinal stromal tumours.

Y. Ge, H. Wang, W. Guan, 2017, Clinical radiology.

Water infusion versus air insufflation for colonoscopy: a meta-analysis of randomized controlled trials

Y. Xu, Y. Sun, Q. Zhu, 2013, Techniques in Coloproctology.

The importance of surgery as the first step in multimodality treatment of small cell bronchial carcinoma. The ISC Lung Cancer Study Group.

M. Liao, Y. Sun, H. Denck, 1990, International journal of clinical pharmacology research.

Safety and pharmacokinetics (PK) of AMG 706 in combination with gemcitabine for the treatment of patients (pts) with solid tumors

L. Lipton, T. Price, M. Rosenthal, 2007 .

Long non-coding RNA FAL1 regulated cell proliferation through Akt pathway via targeting PDK1 in esophageal cancer cells.

Y. Sun, X.-S. Liang, T. Liu, 2018, European review for medical and pharmacological sciences.

Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients.

S. Thongprasert, K. Rau, S. Ye, 2010 .

Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.

Y. Wu, M. Orlando, S. Qin, 2013, Lung cancer.

Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and gemcitabine/cisplatin (GC) for the treatment of advanced solid malignancies.

J. Crawford, J. Gilbert, J. Stephenson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA48 DUBLIN-3 (BPI-2358-103): A global phase (Ph) III trial with the plinabulin/docetaxel (Plin/Doc) combination vs. Doc in 2nd/3rd Line NSCLC patients (pts) with EGFR-wild type (wt) progressing on a prior platinum-based regimen

L. Du, R. Mohanlal, Y. Sun, 2021, Annals of Oncology.

OA02.03 The Third Generation EGFR Inhibitor (EGFR-TKI) HS-10296 in Advanced NSCLC Patients with Resistance to First Generation EGFR-TKI

J. Fang, T. Hsia, J. Chen, 2019, Journal of Thoracic Oncology.

121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC)

Y. Wu, Q. Yu, L. Zhang, 2021, Annals of Oncology.

MA02.01 Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

C. Zhou, Y. Cheng, J. Shao, 2021, Journal of Thoracic Oncology.

MA02.02 Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

Y. Wu, Y. Sun, G. Wu, 2021, Journal of Thoracic Oncology.